Clover Health Investments, Corp. Form 8-K Summary
Business Context and Reporting Period
Clover Health Investments, Corp. filed a Form 8-K concerning a board appointment. The earliest reported event occurred on July 22, 2022; the filing was signed and dated July 26, 2022. The filing does not report quarterly or annual financial results.
Key Financial Metrics and Capital Structure
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial metrics.
Material Changes
- On July 22, 2022, the board appointed Carladenise Armbrister Edwards, Ph.D., Executive Vice President and Chief Strategy Officer of Henry Ford Health System, as a Class III director.
- Dr. Edwards was appointed to the Talent and Compensation Committee and the Nominating and Corporate Governance Committee.
- Her service is subject to the company’s standard director compensation and indemnification arrangements.
Compensation, Governance, and Other Matters
- For 2022, Dr. Edwards will receive a prorated portion of the annual retainers for board and committee service under Clover’s Director Compensation Policy.
- She will receive a restricted stock unit award with a stated value of $200,000, prorated based on service through the September 22, 2022 annual meeting of stockholders.
- She entered into Clover’s standard director indemnification agreement, including indemnification and advancement of expenses for qualifying proceedings.
- The filing states that there were no arrangements or understandings supporting her selection, no family relationships with Clover directors or executive officers, and no reportable related-party interests under Item 404(a) of Regulation S-K.
Investor Verification Items
- Verify the final amount and terms of the prorated RSU award and director retainers.
- Confirm whether Dr. Edwards continued as a director after the September 22, 2022 annual meeting.
- Review Exhibit 99.1, the related press release, noting that the exhibit is dated July 26, 2022 although the reported board action occurred on July 22.
- Review the referenced standard indemnification agreement for the scope of director protections and expense advancement.